ABSORPTION PROFILE AND HORMONAL INFLUENCES OF Fertilized EGG YOLK INGESTION
IN THE HUMAN
Colker. C. Peak Wellness, Inc. Greenwich, CT
Fertile egg yolks contain significant concentrations of follistatin. In an
effort to identify whether this orally ingested source of naturally
occurring follistatin is actually absorbed and pharmacokinetically active in
the human model, this study was undertaken. A male subject was chosen
because the nornma1basline male physiology does not regularly contain any
measurable concentration of follistatin. Follistatin-rich fertile egg yolk
powder properly processed to preserve active follistatin (FolstaxanTM) was
obtained (Celldyne Biopharma, San Antonio, TX). After initial blood draw and
subsequential oral Folstaxan dosing, serum follistatin levels were
qualitatively and quantitatively) measured as an indicator of absorption. In
addition, since we know follistatin is a negative modulator of myostatin,
serum myostatin levels were qualitatively and quantitatively measured as an
indication of hormonal influence and thus true pharmacokinetic activity.
Testing utilized purchased follistatin and myostatin standardized for
verification. Confirmations were run by ELISA and quantitations by Liquid
Chromatography Tandem Mass Spectrometer with third degree fragmentation
(Expertox, Deer Park, TX). Results showed as predicted, a zero level of
follistatin at baseline with a myostatin level of 46 pg/ml, 12 hours after
FolstaxanTM dosing. Serum follistatin measured 57.1 pg/ml with a decline of
myostatin to 34 pg/m1, 24 hours after the initial dosing, follistatin levels
began to predictably drop from the time of initial dosing to 11.4 pg/ml. Yet
myostatin continued to decline slightly with a 24-hour level of 31 pg/ml.
These results clearly indicate that a fertile egg yolk powder properly
processed to preserve active follistatin, when orally ingested, results in
detectable serum follistatin. Furthermore, this resultant follistatin
presence has significant pharmacokinetic activity is shown by the hormonal
down regulation of serum follistatin.